clinical trial · NCT07286266
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
Ovarian NeoplasmsMocertatug rezetecanPaclitaxelPegylated liposomal doxorubicin (PLD)TopotecanGemcitabinePembrolizumabBevacizumab
brief summary
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating ovarian cancer compared to standard treatments. The study also assesses whether Mo-Rez is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of the drug.
started
Jun 18, 2026
primary completion
Jul 22, 2030
completion
Jul 22, 2030
last updated
Oct 15, 2026
official title
A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol